Connect with us

News

NEFIN in Partnership with Hong Kong Baptist Theological Seminary (HKBTS) Embrace Carbon Neutrality for a Green Campus

gbafNews28

316 Solar Panels Built on 6 Rooftops of HKBTS Campus Buildings

 

HONG KONG SAR – Media OutReach – 5 January 2021 – NEFIN, a leading solar developer and investor in carbon neutrality solutions in Asia, is pleased to announce the implementation of four holistic solar PV systems in the main campus of Hong Kong Baptist Theological Seminary (HKBTS), one of the established seminaries in Hong Kong.  The four solar PV systems cover six rooftops in the campus.

[View Image]

“It is our pleasure and honour to work with HKBTS to transform their extensive building rooftops into highly-effective solar energy generating fields. Despite social unrest and the outbreak of COVID-19, the project was brought seamlessly to completion.  The NEFIN-HKBTS partnership is exemplary of the flexibility, expertise and operational skills of NEFIN as well as the trust that HKBTS has in us.We are proud to share this piece of positive news to kick off 2021.” said Clara Kwan, COO of NEFIN Group.

The 316 solar PV panels installed can generate approximately 152,559 kWh annually, offsetting 78 tons CO2 emission per year. The scale of this installation would be equivalent to planting 1,297 trees for the earth.

“A Green and Glossy Gospel: God’s creative love is extended to all God’s creations, calling God’s followers to bear the responsibilities for nature and to testify to the reconciliation and peace of the universe.” commented by President Cho of HKBTS.

“NEFIN has successfully completed several projects around Asia in 2020, amidst the challenges of the pandemic. One of the NEFIN’s beliefs is that the effort to achieve carbon neutrality should not be halted as a result of current temporary setbacks. With another challenging year ahead, enterprises should be prepared for future climate challenges, which may be sooner or least expected, like the COVID19 pandemic,” commented Mr. Glenn Lim, CEO of NEFIN.

About HKBTS

Established in 1951, the HKBTS was founded on Baptist heritage. The objective of the Seminary is to cultivate servant leadership in those called by God to serve the churches in face of social and global challenges. In addition to the Ministerial Preparation Program and Graduate School, the Seminary offers Distance Education Program, Lay Leadership Training Program, Pastoral Continuing Education Program, and Music and Art Education Program. For further information, visit www.hkbts.edu.hk.


About NEFIN Group


NEFIN Group is a regional renowned solar developer with bespoke experience in solar system deployment and a committed partner to organisations that aim to achieve carbon neutrality. Founded by a core management team of DuPont Solar Business, legal experts, and investment bankers, NEFIN Group has collectively delivered over 300MW of utility-scale, commercial, and industrial rooftop solar systems regionally. The group offers consulting services such as due diligence, feasibility studies, and lender-technical advice on top of project development, system design, engineering, and asset management. NEFIN Group also offers flexible financing options to partners who opt for zero investment. Please refer to NEFIN’s website www.nefinco.com  for more information.

News

Rapha Capital Management Announces Successful Initial Public Offering of Portfolio Company NexImmune Inc.

gbafNews28

MIAMI, Feb. 24, 2021 /PRNewswire/ — Rapha Capital Management, LLC (https://raphacap.com), an investment management firm located in Miami, Florida, is pleased to announce that on February 17, 2021, its portfolio company, NexImmune, Inc. (“NexImmune”), closed an upsized initial public offering raising gross proceeds, before deducting underwriting discounts and commissions and offering expenses, of approximately $126.5 million. The gross proceeds included the exercise in full by the underwriters of their option to purchase additional shares. NexImmune's shares are traded on the Nasdaq Global Market under the symbol “NEXI”.  Rapha Capital Investment II, LLC (“RCI II”) (an entity managed by Rapha Capital), participated in NexImmune's Series A financing in July, 2018 and Series A-2 financing in January, 2019, investing a total of $1.8 million

Rapha Capital Management is an investment management firm focused on managing strategic investments in early stage, non-public biotechnology companies, through special purpose investment vehicles (“SPIVs”).  Rapha Capital was founded by its President, Kevin Slawin, M.D., a successful and experienced oncologic and robotic surgeon.  After leaving practice, Dr. Slawin has been serving as a biotech consultant, investor, and founder, focusing on disruptive technologies in oncology, T cells and immunotherapy, and other breakthrough healthcare technologies.  He is the founder of Bellicum Pharmaceuticals, Inc. (“Bellicum”), a publicly traded company listed on NASDAQ, leading Bellicum to a successful $161 million IPO in December, 2014.  He also plays a guiding role in several of the investments managed by Rapha Capital in certain companies, serving as a board member at 3DBio Therapeutics, Inc. (https://3dbiocorp.com/), FIZE Medical, Inc. (www.fizemedical.com), and Demeetra AgBio, Inc. (www.demeetra.com).  He served as a board member and interim CEO of portfolio company AsclepiX Therapeutics, Inc. (www.asclepix.com) in 2020, engineering their $35 million Series A financing led by Perceptive Xontogeny Venture Fund in mid 2020.  Rapha Capital Management manages thirteen legacy SPIVs, Rapha Capital Investment I – XIII.  Rapha Capital Management will be offering alternative asset management services to its inaugural venture capital fund, launching at the end of 1Q21, which will be the vehicle for all future investments managed by Rapha Capital Management.

“We recognized the transformative potential of immunotherapy early on, founding Bellicum Pharmaceuticals, one of the first cellular immunotherapy companies in 2004, and have been an expert in identifying other potentially disruptive technologies, since 2017, when Rapha Capital Management was founded,” commented Kevin Slawin, MD.  “RCI II's investment in NexImmune is another example of our commitment to use our unique abilities to identify at the earliest stage, those companies that we believe will go on to profoundly improve peoples' lives while building great value, from a sea of seemingly indistinguishable, less compelling, opportunities,” he added.

About NexImmune, Inc.
NexImmune, based in Gaithersburg, Maryland, is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's own T cells to generate a specific, potent and durable immune response that mimics natural biology.  NexImmune's IPO pricing announcement can be accessed here.

About Rapha Capital Management, LLC
Rapha Capital Management, LLC is an investment management firm located in Miami, Florida, focusing on identifying and managing strategic investments in early stage, non-public biotechnology companies.  Rapha Capital was founded by its President, Kevin Slawin, MD, a successful and experienced oncologic and robotic surgeon, biotech consultant, investor, and founder focusing on technologies in oncology, T cells and immunotherapy, as well as other breakthrough healthcare technologies.  He is the founder of Bellicum Pharmaceuticals, Inc., a publicly traded company listed on NASDAQ.  He is co-Inventor of the FDA,-approved “prostate health index (phi)” test licensed and marketed by Beckman Coulter and utilized around the world.  He has published extensively in top medical and scientific journals including the Journal of the American Medical Association (JAMA), Journal of the National Cancer Institute (JNCI), and the New England Journal of Medicine (NEJM)He has also been routinely listed in America's Top Doctors for Cancer (Castle Connolly Medical) and The Best Doctors in America (Woodward/White).  In 2003, he was awarded the F. Brantley Scott, Jr., Award for Innovation and Creativity in Urology.

For more information email [email protected] or visit https://www.raphacap.com

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/rapha-capital-management-announces-successful-initial-public-offering-of-portfolio-company-neximmune-inc-301234097.html

SOURCE Rapha Capital Management, LLC

Continue Reading

News

Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2020 and Highlights Recent Corporate Updates

gbafNews28

SAN DIEGO, Feb. 24, 2021 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced financial results for the three and twelve months ended December 31, 2020 and highlighted recent corporate updates.

Recent Corporate Updates

Pain Management Franchise

  • New Drug Application Resubmission for HTX-011 Under Review: The New Drug Application (NDA) resubmission for HTX-011, an investigational agent for the management of postoperative pain, submitted November 12, 2020 to the U.S. Food and Drug Administration (FDA), continues under review. The FDA set a Prescription Drug User Fee Act (PDUFA) goal date of May 12, 2021.
  • European Commission Authorization for ZYNRELEF™ for the Treatment of Postoperative Pain: In September 2020, the European Commission (EC) granted a marketing authorization for ZYNRELEF (formerly known as HTX-011) for the treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults. As Heron builds large-scale manufacturing capacity to meet the anticipated commercial demand in the U.S. and the rest of the world, we are developing a coordinated global marketing strategy. At this time, Heron anticipates making ZYNRELEF available to patients in Europe during 2022.
  • Low-Dose HTX-034 Produced Greater Pain Reduction Compared to Bupivacaine, the Current Standard-of-Care, Through 96 Hours in Bunionectomy Study: In the Phase 1b portion of this Phase 1b/2 double-blind, randomized, active-controlled, dose-escalation study in 33 patients undergoing bunionectomy, the reduction in pain intensity observed was greater with the lowest dose of HTX-034 evaluated (containing 21.7 mg of bupivacaine plus meloxicam and aprepitant) than with the bupivacaine 50 mg solution through 96 hours.
  • In addition, 45.5% of HTX-034 patients remained opioid-free through Day 15 with median opioid consumption of 2.5 mg morphine equivalents (same as one 5 mg oxycodone pill) through 72 hours, a 71% reduction compared to bupivacaine solution.
  • Heron expects to initiate the expanded Phase 2 portion of the study for HTX-034 in the first quarter of 2021.

CINV Franchise

  • CINV 2020 Net Product Sales: For the three and twelve months ended December 31, 2020, chemotherapy-induced nausea and vomiting (CINV) franchise net product sales were $20.6 million and $88.6 million, respectively, compared to $35.1 million and $146.0 million for the same periods in 2019.
  • CINVANTI® Net Product Sales: Net product sales of CINVANTI (aprepitant) injectable emulsion for the three and twelve months ended December 31, 2020 were $20.3 million and $87.8 million, respectively, compared to $34.6 million and $132.2 million, respectively, for the same periods in 2019. Heron believes the most significant impact of the generic arbitrage is over and expects to grow CINVANTI market share in 2021 and beyond.
  • SUSTOL® Net Product Sales: Net product sales of SUSTOL (granisetron) extended-release injection for the three and twelve months ended December 31, 2020 were $0.3 million and $0.8 million, respectively, compared to $0.5 million and $13.8 million for the same periods in 2019. On October 1, 2019, we discontinued all discounting of SUSTOL to improve the reimbursement and net selling price of the product, which resulted in significantly lower SUSTOL net product sales in 2020. Heron expects SUSTOL to return to growth in 2021 and beyond.
  • Full-Year 2021 Net Product Sales Guidance: Heron expects full-year 2021 net product sales for the CINV franchise of $130 million to $145 million.
  • HTX-019 for PONV

    • HTX-019 Achieved Bioequivalence to Approved Oral Aprepitant 40 mg Dose for Prevention of PONV: A new Investigational New Drug application for HTX-019 (aprepitant injectable emulsion) for postoperative nausea and vomiting (PONV) was approved by the FDA in late September of 2020. In the Phase 1 bioequivalence study, 32 mg of HTX-019 as a 30-second intravenous (IV) injection was bioequivalent to oral aprepitant 40 mg, which is approved for the prevention of PONV. An NDA for HTX-019 is planned in late 2021 for prevention of PONV in adults.

    Corporate Update

    • Year-End 2020 Cash Balance: Heron ended 2020 with $208.5 million in cash, cash equivalents and short-term investments.

    “We are very pleased that we exceeded our CINV sales guidance for the year, despite 2020 being a challenging year for Heron, with our CINV franchise impacted by both the COVID-19 global pandemic and the EMEND® IV generic arbitrage. We also achieved several important milestones in 2020, including the authorization of ZYNRELEF in Europe and the advancement of HTX-034 for postoperative pain and HTX-019 for PONV into clinical development,” said Barry Quart, Pharm.D., Chairman and Chief Executive Officer of Heron. “We believe that 2021 will be a transformational year for Heron, with significant growth expected in our CINV products with net product sales guidance of $130 million to $145 million, the anticipated FDA approval and commercial launch of HTX-011 in the U.S., and the submission of an NDA for HTX-019 for PONV in the fourth quarter.”                                                         

    Financial Results

    Net product sales for the three and twelve months ended December 31, 2020 were $20.6 million and $88.6 million, respectively, compared to $35.1 million and $146.0 million, respectively, for the same periods in 2019.

    Heron's net loss for the three and twelve months ended December 31, 2020 was $62.3 million and $227.3 million, or $0.68 per share and $2.50 per share, respectively, compared to $57.9 million and $204.7 million, or $0.65 per share and $2.50 per share, respectively, for the same periods in 2019. Net loss for the three and twelve months ended December 31, 2020 included non-cash, stock-based compensation expense of $16.0 million and $50.2 million, respectively, compared to $11.1 million and $51.4 million, respectively, for the same periods in 2019.

    As of December 31, 2020, Heron had cash, cash equivalents and short-term investments of $208.5 million compared to $391.0 million as of December 31, 2019. Net cash used for operating activities for the twelve months ended December 31, 2020 was $184.8 million, compared to $124.6 million for the same period in 2019. Heron expects that its current cash, cash equivalents and short-term investments will be sufficient to fund its operations into 2022.

    About HTX-011 for Postoperative Pain (ZYNRELEF in Europe)

    HTX-011, an investigational non-opioid analgesic, is a dual-acting, fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam. It is the first and only extended-release local anesthetic to demonstrate in Phase 3 studies significantly reduced pain and opioid use through 72 hours compared to bupivacaine solution, the current standard-of-care local anesthetic for postoperative pain control. The FDA granted Breakthrough Therapy designation to HTX-011 and the NDA received Priority Review designation. A complete response letter was received from the FDA regarding the NDA for HTX-011 in June 2020 relating to non-clinical information. No clinical safety or efficacy issues and no chemistry, manufacturing and controls issues were identified. Heron resubmitted an NDA to the FDA for HTX-011 in November 2020 and the FDA set a PDUFA goal date of May 12, 2021. Heron is working to respond to a list of questions received from Health Canada in July 2020. In September 2020, the EC granted a marketing authorization for ZYNRELEF (also known as HTX-011) for the treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults. The EC's centralized marketing authorization is valid for the 27 countries that are members of the European Union, the other countries in the European Economic Area, and the United Kingdom.

    About HTX-034 for Postoperative Pain

    HTX-034, an investigational non-opioid analgesic, is a triple-acting, fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam and aprepitant, an additional agent that further potentiates the activity of bupivacaine. HTX-034 is formulated in the same proprietary polymer as HTX-011. By combining two different mechanisms that each enhance the activity of the local anesthetic bupivacaine, HTX-034 is designed to provide superior and prolonged analgesia. Local administration of HTX-034 in a validated preclinical postoperative pain model resulted in sustained analgesia for 7 days.

    About HTX-019 for Postoperative Nausea and Vomiting

    HTX-019 is an IV injectable emulsion formulation designed to directly deliver aprepitant, the active ingredient in EMEND® (aprepitant) capsules, which is the only substance P/neurokinin-1 (NK1) receptor antagonist (RA) to be approved in the U.S. for the prevention of PONV in adults. The FDA-approved dose of oral EMEND is 40 mg for PONV, which is given within 3 hours prior to induction of anesthesia for surgery. In a Phase 1 clinical trial, 32 mg of HTX-019 as a 30-second IV injection was demonstrated to be bioequivalent to oral aprepitant 40 mg.

    About CINVANTI (Aprepitant) Injectable Emulsion

    CINVANTI, in combination with other antiemetic agents, is indicated in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin as a single-dose regimen, delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) as a single-dose regimen, and nausea and vomiting associated with initial and repeat courses of MEC as a 3-day regimen. CINVANTI is an IV formulation of aprepitant, an NK1 RA. CINVANTI is the first IV formulation to directly deliver aprepitant, the active ingredient in EMEND® capsules. Aprepitant (including its prodrug, fosaprepitant) is the only single-agent NK1 RA to significantly reduce nausea and vomiting in both the acute phase (0–24 hours after chemotherapy) and the delayed phase (24–120 hours after chemotherapy). The FDA-approved dosing administration included in the U.S. prescribing information for CINVANTI is a 30-minute IV infusion or a 2-minute IV injection.

    CINVANTI is under investigation for the treatment of COVID-19 as a daily 2-minute IV injection when added to the current standard of care.

    Please see full prescribing information at www.CINVANTI.com.

    About SUSTOL (Granisetron) Extended-Release Injection

    SUSTOL is indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. SUSTOL is an extended-release, injectable 5-HT3 RA that utilizes Heron's Biochronomer® drug delivery technology to maintain therapeutic levels of granisetron for ≥5 days. The SUSTOL global Phase 3 development program was comprised of two, large, guideline-based clinical studies that evaluated SUSTOL's efficacy and safety in more than 2,000 patients with cancer. SUSTOL's efficacy in preventing nausea and vomiting was evaluated in both the acute phase (0–24 hours after chemotherapy) and delayed phase (24–120 hours after chemotherapy).

    Please see full prescribing information at www.SUSTOL.com.

    About Heron Therapeutics, Inc.

    Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs. Heron is developing novel, patient-focused solutions that apply its innovative science and technologies to already-approved pharmacological agents for patients suffering from pain or cancer. For more information, visit www.herontx.com.

    Forward-looking Statements

    This news release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to, those associated with: whether the FDA approves the NDA for HTX-011; the timing of the commercial launch of HTX-011 in the U.S., if approved; the timing of the commercial launch of ZYNRELEF in Europe; the timing of Health Canada's New Drug Submission (NDS) review process for HTX-011; whether Health Canada issues a Notice of Compliance for the NDS for HTX-011; the timing and results of studies for the HTX-034 and HTX-019 development programs; the full-year 2021 net product sales guidance for the CINV franchise; the expected future balances of Heron's cash, cash equivalents and short-term investments; the expected duration over which Heron's cash, cash equivalents and short-term investments balances will fund its operations; the extent of the impact of the ongoing Coronavirus Disease 2019 pandemic on our business; and other risks and uncertainties identified in the Company's filings with the U.S. Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.

     

    Heron Therapeutics, Inc.

    Consolidated Statements of Operations

    (In thousands, except per share amounts)

    Three Months Ended

    Twelve Months Ended

    December 31,

    December 31,

    2020

    2019

    2020

    2019

    (Unaudited)

    Revenues:

    Net product sales

    $        20,605

    $        35,083

    $        88,638

    $      145,968

    Operating expenses:

    Cost of product sales

    9,392

    15,874

    36,189

    61,619

    Research and development

    44,453

    48,277

    174,533

    167,382

    General and administrative

    12,503

    9,874

    42,226

    37,897

    Sales and marketing

    15,553

    20,420

    63,853

    89,764

    Total operating expenses

    81,901

    94,445

    316,801

    356,662

    Loss from operations

    (61,296)

    (59,362)

    (228,163)

    (210,694)

    Other income (expense), net

    (985)

    1,442

    885

    5,945

    Net loss

    $      (62,281)

    $      (57,920)

    $    (227,278)

    $    (204,749)

    Basic and diluted net loss per share

    $          (0.68)

    $          (0.65)

    $          (2.50)

    $          (2.50)

    Shares used in computing basic and diluted net loss per share

    91,081

    89,112

    90,774

    81,779

     

    Heron Therapeutics, Inc.

    Consolidated Balance Sheets

    (in thousands)

    December 31,
    2020

    December 31,
    2019

    ASSETS

    Current assets:

    Cash and cash equivalents

    $               105,138

    $               71,898

    Short-term investments

    103,353

    319,074

    Accounts receivable, net

    41,850

    39,879

    Inventory

    41,905

    24,968

    Prepaid expenses and other current assets

    21,950

    23,245

    Total current assets

    314,196

    479,064

    Property and equipment, net

    22,737

    19,618

    Right-of-use lease assets

    16,277

    13,754

    Other assets

    346

    346

    Total assets

    $             353,556

    $            512,782

    LIABILITIES AND STOCKHOLDERS' EQUITY

    Current liabilities:

    Accounts payable

    $                    525

    $                2,758

    Accrued clinical and manufacturing liabilities

    49,962

    34,614

    Accrued payroll and employee liabilities

    13,597

    15,248

    Other accrued liabilities

    28,369

    36,535

    Current lease liabilities

    2,997

    1,926

    Convertible notes payable to related parties

    7,053

    5,624

    Total current liabilities

    102,503

    96,705

    Non-current lease liabilities

    14,561

    12,242

    Total liabilities

    117,064

    108,947

    Stockholders' equity:

            Preferred stock

            Common stock

    913

    903

    Additional paid-in capital

    1,628,070

    1,568,317

    Accumulated other comprehensive income

    257

    85

    Accumulated deficit

    (1,392,748)

    (1,165,470)

    Total stockholders' equity

    236,492

    403,835

    Total liabilities and stockholders' equity

    $             353,556

    $            512,782

     

    Investor Relations and Media Contact:
    David Szekeres
    Executive Vice President, Chief Operating Officer
    Heron Therapeutics, Inc.
    [email protected] 
    858-251-4447

    Cision View original content:http://www.prnewswire.com/news-releases/heron-therapeutics-announces-financial-results-for-the-three-and-twelve-months-ended-december-31-2020-and-highlights-recent-corporate-updates-301234154.html

    SOURCE Heron Therapeutics, Inc.

    Continue Reading

    News

    SOS Announces the Receipt of the Second Batch of 5000 Pieces of Crypto Mining Rigs

    gbafNews28

    QINGDAO, China, Feb. 24, 2021 /PRNewswire/ — SOS Limited (NYSE: SOS) (the “Company” or “SOS”) announced today the receipt of the second batch of 5000 PCS of crypto mining rigs.

    On the same date the second batch of 5000 PCS of mining rigs were received, the SOS team kicked off the configurations and installations, which are expected to be completed very soon. Once this batch of mining rigs goes live, we expect the pool of 5000 PCS will be able to generate about BTC Hash Power 175P and ETH Hash Power 350G. If the machine operates as expected, the long-term ROI (return on investment) is projected to be promising, despite recent pullbacks of cryptocurrency prices.

    Mr. Yandai Wang, Chairman of SOS, commented, “Although the cryptocurrency prices, such as BTC prices, might continue to fluctuate, we believe the big general trend for and cycle of cryptocurrencies are still upward. As institutional investors have been becoming one significant driving force behind cryptocurrencies, such as BTC and ETH, which will be utilized as a hedge against ongoing quantitative easing by sovereign currencies, therefore, we remain committed to be very confident about our long-term strategic investment in cryptocurrencies operation.”

    About SOS Limited

    SOS is an emerging blockchain-based and big data-driven marketing and solution provider, with a nationwide membership base of approximately 20 million in China. Recently, SOS has outlined its strategy in blockchain and cryptocurrencies, which include a series of initiatives to expand its business into cryptocurrency mining as well as cryptocurrency security and insurance. The core infrastructure of SOS' marketing data, technology and solutions to insurance and emergency rescue services is built on big data, blockchain-based technology, cloud computing, AI, satellite, and 5G network, etc. SOS has created a cloud “software as a service (SaaS)” platform for emergency rescue services, with three major product categories: basic cloud, cooperative cloud, and information. This system provides innovative marketing solutions to clients such as insurance companies, financial institutions, medical institutions, healthcare providers, auto manufacturers, security providers, senior living assistance providers, and other service providers in the emergency rescue services industry.

    SOS has obtained a national high-tech enterprise certification and the title of “Big Data Star Enterprise,” awarded by Gui'an New District Government. Staying on the forefront of digital technology innovation, the Company has registered 99 software copyrights and 2 patents. For more information, please visit: http://www.sosyun.com/.

    Forward-Looking Statements

    Certain statements made herein are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include timing of the proposed transaction; the business plans, objectives, expectations and intentions of the parties;, SOS's estimated and future results of operations, business strategies, competitive position, industry environment and potential growth opportunities market acceptance of our products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on our business, our research programs, healthcare systems or the global economy as a whole; our intellectual property; our reliance on third party organizations; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our product offering, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets; and our cash needs and financing plans and etc. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. SOS may not realize its expectations, and its beliefs may not prove correct. Due to known and unknown risks, our actual results may differ materially from our expectations or projections. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

    Additional information concerning these and other factors that may impact our expectations and projections can be found in our periodic filings with the SEC, including our Annual Report on Form 20-F for the fiscal year ended December 31, 2019. SOS's SEC filings are available publicly on the SEC's website at www.sec.gov. SOS disclaims any obligation to update the forward-looking statements, whether as a result of new information, future events or otherwise.

    Cision View original content:http://www.prnewswire.com/news-releases/sos-announces-the-receipt-of-the-second-batch-of-5000-pieces-of-crypto-mining-rigs-301234528.html

    SOURCE SOS Limited

    Continue Reading
    Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.

    Call for Entries

    Global Banking and Finance Review Awards Nominations 2021
    2021 Awards now open. Click Here to Nominate

    Latest Posts

    gbafNews28 gbafNews28
    News35 mins ago

    Rapha Capital Management Announces Successful Initial Public Offering of Portfolio Company NexImmune Inc.

    MIAMI, Feb. 24, 2021 /PRNewswire/ — Rapha Capital Management, LLC (https://raphacap.com), an investment management firm located in Miami, Florida, is...

    gbafNews28 gbafNews28
    News35 mins ago

    SOS Announces the Receipt of the Second Batch of 5000 Pieces of Crypto Mining Rigs

    QINGDAO, China, Feb. 24, 2021 /PRNewswire/ — SOS Limited (NYSE: SOS) (the “Company” or “SOS”) announced today the receipt of...

    gbafNews28 gbafNews28
    News35 mins ago

    Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2020 and Highlights Recent Corporate Updates

    SAN DIEGO, Feb. 24, 2021 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the...

    gbafNews28 gbafNews28
    News35 mins ago

    ZK International's Subsidiary, xSigma Corporation, Announces a Software Acquisition Deal and the Launch of its Crypto Trading Platform

    WENZHOU, China, Feb. 24, 2021 /PRNewswire/ — ZK International Group Co., Ltd. (Nasdaq: ZKIN) (“ZKIN”, “ZK International” or the “Company”), is pleased to...

    gbafNews28 gbafNews28
    News35 mins ago

    Hawkeye Systems Finalizes terms with IKON supplies

    SAVANNAH, Georgia, Feb. 24, 2021  PR Newswire – Hawkeye Systems, Inc. (OTCQB: HWKE) is pleased to announce that we have...

    gbafNews28 gbafNews28
    News36 mins ago

    OneUnited Bank, Largest Black Owned Bank Introduces Solidarity Card For Black History Month

    LOS ANGELES, Feb. 24, 2021 /PRNewswire/ — OneUnited Bank, the largest Black owned bank and first and only Black owned digital...

    gbafNews28 gbafNews28
    News36 mins ago

    Thinking about buying stock in Sundial Growers, electroCore, Arlo Technologies, Salarius Pharmaceuticals, or CNS Pharmaceuticals?

    NEW YORK, Feb. 24, 2021 /PRNewswire/ — InvestorsObserver issues critical PriceWatch Alerts for SNDL, ECOR, ARLO, SLRX, and CNSP. To...

    gbafNews28 gbafNews28
    News36 mins ago

    Deloitte: The Future of Racial Equity Depends on Business Taking Bold Action Now

    NEW YORK, Feb. 24, 2021 /PRNewswire/ — Key takeaways Deloitte conducted extensive research and more than 50 interviews with a...

    gbafNews28 gbafNews28
    News36 mins ago

    NetObjex Is one of 11 Startups Chosen out of 198 Total Applicants to Participate in Algorand Europe Accelerator

    IRVINE, Calif., Feb. 24, 2021 /PRNewswire/ — NetObjex is one of 11 startups chosen out of 198 total applicants and...

    gbafNews28 gbafNews28
    News36 mins ago

    Bidi Vapor Advances to Final Substantive Review Phase of the FDA PMTA Process for all 11 Bidi® Stick Flavors

    GRANT, Fla., Feb. 24, 2021 /PRNewswire/ — Kaival Brands Innovations Group, Inc. (OTCQB: KAVL) (“Kaival Brands,” the “Company,” or “we”), is...